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Abstract
Purpose Obstructive sleep apnea (OSA) and chronic ob-
structive pulmonary disease (COPD) have been known to
be associated with atherosclerosis and hypoxia which was
suggested to have an important role in this process by the
way of increased oxidative stress. In the present study, we
aimed to evaluate the effects of nocturnal hypoxia pattern
(intermittent versus sustained) on serum lipid peroxidation
and paraoxonase (PON) activity.
Methods Blood collections were performed in 44 OSA, 11
non-apneic, nocturnal desaturated COPD, and 14 simple
snorer patients after full-night polysomnographic record-
ings. Nocturnal sleep and respiratory parameters, oxygen
desaturation indexes, serum malondialdehyde (MDA) levels
by measuring with the help of the formation of thiobarbitu-
ric acid reactive substances (TBARS), and PON activity
were assessed in all subjects.
Results OSA and COPD patients showed nocturnal hypox-
emia, with a minimum oxygen saturation (SaO2) in ranges
of 53–92 % and 50–87 %, respectively. The mean levels of
TBARS was 15.7±3.6 nmol and 15.3±3.4 nmol malondial-
dehyde (MDA)/ml in OSA and COPD patients, respectively,
while the mean level of the control group was 4.1±1.2 nmol
MDA/ml. The mean PON activity was found to be 124.2±
35.5 U/l in OSA patients and 124.6±28.4 U/l in COPD
patients. The mean PON activity of the control group was
269.0±135.8 U/l. The increase in TBARS levels and the
decrease in PON1 levels were statistically significant in both
OSA and COPD patients according to controls (p<0.001 for
TBARS as well as PON1).
Conclusion The results of this study revealed that both OSA
and non-apneic, nocturnal desaturated COPD patients
showed increased levels of lipid peroxidation and decreased
PON activity despite the differences in nocturnal hypoxia
pattern.
Keywords Intermittent hypoxia . Obstructive sleep apnea .
Chronic obstructive pulmonary disease . Paraoxonase . Lipid
peroxidation . Oxidative stress
Introduction
Obstructive sleep apnea syndrome (OSAS) is a disease
characterized by repetitive obstruction of the upper airway
resulting in an oxygen desaturation, arousal from sleep, and
excessive daytime sleepiness. In recent years, OSAS has
been associated with cardiovascular diseases such as coro-
nary artery diseases and cerebrovascular events [1, 2].
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Intermittent hypoxia–reoxygenation due to repetitive abnor-
mal obstructive events throughout the night is thought to
cause the production of free radicals, oxidative stress, and
eventually atherosclerosis. Also, patients with chronic ob-
structive pulmonary disease(COPD) have been reported that
there is a significantly higher risk of death from myocardial
infarction and they show signs of atherosclerosis which is
associated with endothelial dysfunction, hypoxemia, and
increased levels of oxidative stress and inflammation bio-
markers [3–6].
In OSA, oxygen desaturation occurs in a cyclic manner.
Cyclic intermittent hypoxia throughout the night was pro-
posed to be the cause of endothelial dysfunction in OSA
patients with early signs of atherosclerosis [7]. Nocturnal
desaturation in COPD has been described primarily as REM
sleep-associated and occurring in a sustained drop pattern
[8]. Nocturnal hypoxemia in COPD is associated with com-
plications, such as arrhythmia and pulmonary hypertension
[9], but the association between nocturnal hypoxemia and
atherosclerosis has not been investigated previously [10, 11].
High lipid level is one of the major risk factors for
cardiovascular diseases. Early development of atherosclero-
sis may be associated with disorders of lipid metabolism,
especially disorders causing lower plasma levels of high
density lipoprotein-cholesterol (HDL-C). The HDL-C has
been hypothesized to support the efflux of cholesterol from
the artery wall or protect the low density lipoprotein (LDL)
particle and cell membranes from lipid peroxide-mediated
damage [12]. As an HDL-associated enzyme, PON is im-
portant for protection of LDL from oxidative modification,
which plays a particular role in the development of athero-
sclerosis [12].
Lavie et al. demonstrated increased levels of lipid perox-
idation products and low paraoxonase (PON) 1 levels in
OSA patients with cardiovascular diseases and suggested
that increased oxidative stress might have a role in cardio-
vascular morbidity in OSAS. Respiratory disturbance index
was a major predictor of an increased oxidative stress in
OSA, leading Lavie to propose that intermittent hypoxia
was a result of repeated abnormal obstructive events [13].
On the other hand, Yamauchi et al. showed an association
between increased oxidative stress markers and oxygen
desaturation indexes [14], and Minoguchi et al. implicated
the significant correlation between the duration of hypoxia
and a lipid peroxidation marker of urinary 8-isoprostane
excretion that was suggested to be the result of intermittent
hypoxia during the night [15]. Meanwhile, there are several
studies about lipid peroxidation and oxidative stress in
COPD patients, and increased lipid peroxidation and re-
duced antioxidant status were documented [16].
Both hypoxia and reoxygenation are important in human
pathophysiology. It was postulated that transient hypoxia is
followed by cellular reoxygenation injury. Reoxygenation
worsens hypoxic injury by increasing reactive oxygen spe-
cies (ROS) production [17, 18], which is implicated in post-
hypoxic cellular injury [19]. Moreover, oxidative stress has
been described as an imbalance between ROS production
and the capability of biological systems to eliminate reactive
intermediates. These reactive intermediates are major com-
ponents in the pathophysiology of atherogenesis. In OSA
patients, cyclic changes in oxygen saturation due to apnea
and hypopnea could be thought of as an analogous to
ischemia–reoxygenation injury. Initiation of ROS produc-
tion and repeated cyclic hypoxia–reoxygenation may in-
crease oxidative stress and consequently may have a role
in the cardiovascular pathologies frequently reported in
OSA patients [20]. Atherosclerosis in COPD patients was
postulated that a reduction in flow volumes was a predictive
parameter for increased risk of cardiovascular diseases [21,
22]. To the best of our knowledge, the role of nocturnal
sustained hypoxia in oxidative stress in daytime normoxic
COPD patients has not been reported yet. We thought that
nocturnal hypoxemia (seen in either OSA or COPD) might
have a role in an increasing oxidative stress that would be
evidenced by increased TBARS levels and decreased PON1
activity in both patient groups according to controls.
The purpose of this study was to compare the effect of
nocturnal cyclic intermittent hypoxia and sustained intermit-
tent hypoxia on the lipid peroxidation product TBARS and
an antioxidant enzyme, PON1. In order to evaluate whether
patterns of nocturnal hypoxia affected some parts of the
oxidative stress pathway, we compared COPD patients with
nocturnal long-term desaturation but normal daytime satu-
ration levels to OSA patients and simple snorers.
Materials and methods
Subjects
This is a retrospective analysis of a group of patients of
whom parameters are recorded prospectively. The study was
conducted between April 2009 and April 2010, after ap-
proval by the Ethics Committee of the Marmara Medical
Faculty (MAR.0.01.02/AEK/895). All volunteers provided
a written informed consent before participation in the study.
In this study, 44 patients with newly diagnosed OSA, 11
non-apneic COPD patients, and 14 control subjects classi-
fied as simple snorers were enrolled.
OSA patients (five women, 39 men) were admitted to the
sleep clinic for an initial evaluation, and they had symptoms
consistent with sleep apnea as defined by a sleep specialist.
Diagnosis of OSA was based on the clinical history,
Epworth Sleepiness Scale (ESS) scores [23], and polysom-
nography (PSG) findings. The diagnosis of OSAS was
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confirmed by an apnea–hypopnea index (AHI) of >5 epi-
sodes/h of sleep after a full-night PSG.
The non-apneic COPD group (three women, eight men)
consisted of 11 stable COPD patients with continuous hyp-
oxemia during sleep as measured by PSG. All patients in
this group showed greater than 60 mmHg partial arterial
oxygen saturation (PaO2) during the daytime. Nocturnal
oxygen saturation recordings demonstrated more than
30 % of total sleep time with a PaO2 of less than 90 % in
this group. Diagnosis of COPD was based on the European
Respiratory Society (ERS) guidelines [24]. A clinical diag-
nosis of COPD was characterized by chronic cough, exer-
tional dyspnea, or wheezing. Spirometry was performed
using a Vitalograph spirometer (Zan, Messgeraete GmbH
Germany). Forced vital capacity (FVC) and forced expira-
tory volume in 1-s (FEV1) measurements were recorded,
and the FEV1/FVC ratios were calculated. Airflow limita-
tion was diagnosed when FEV1/FVC was less than 0.7.
None of the patients were oxygen dependent and none used
bronchodilator treatments. Subjects diagnosed with obstruc-
tive or central apnea were not included in the study group.
The control group consisted of 14 patients (three women,
11 men) with symptoms suggestive of OSAS-like snoring,
history of apnea, and daytime sleepiness. Polysomnographic
findings for this group were compatible with simple snoring
with AHI <5.
The exclusion criteria for the study were as follows: (1)
connective tissue disorders and metabolic or neurologic
disorders inducing peripheral neuropathy (e.g., diabetes
mellitus), (2) personal or family history of psychiatric dis-
orders, (3) history of alcohol and drug abuse, (4) infectious
diseases, (5) medical illnesses such as cancer and neuromus-
cular diseases, and (6) use of anti-lipidemic drugs. Patients
with histories of cardiac failure were also excluded. The
existence of confounding risk factors was determined by
routine history analysis and proper medical documentation,
physical examination, including blood pressure measurement
and laboratory assessments, including total cholesterol, tri-
glyceride, HDL, LDL, and serum fasting glucose levels.
Sleep study
Nocturnal polygraphic recordings included the following
variables: electroencephalogram (F3/A2, F4/A1, C3/A2,
C4/A1 O1/A2, and O2/A1 according to the 10–20 interna-
tional electrode placement system), electrooculogram, and
chin and anterior tibialis electromyogram and electrocardio-
gram. Respiration was analyzed with oronasal airflow and
thoracic and abdominal strain gauges. Snoring was evaluat-
ed with a microphone placed above the larynx. Body posi-
tion was monitored using a body-position sensor. Oxygen
saturation during sleep was measured continuously by
finger oximetry. Total sleep time of less than 6 h of the total
recording time were not evaluated.
Nocturnal recordings were scored according to the standard
criteria of the American Academy of Sleep Medicine [25] in
30-s epoch. An apnea was defined as a cessation of airflow
with a duration of ≥10 s. Hypopnea was defined as a ≥50 %
reduction in airflow relative to baseline, associated with either
arousal or oxygen desaturation of ≥3 %. AHI was calculated
as the number of abnormal respiratory events per hour of
sleep. As an index of nocturnal oxygen saturation, the mini-
mum oxygen saturation (min O2), oxygen desaturation index
(ODI), and percentage of total sleep time with an oxygen
saturation (SaO2) <90 % were used. Nocturnal continuous
hypoxemia was defined as spending more than 30 % of total
sleep time with a SaO2 <90 %.
All blood samples were collected in the morning after an
overnight fast, and serum samples were stored at −70°C
until they were assayed for paraoxonase 1 (PON1) activity
and TBARS levels.
Paraoxonase activity assay
Paraoxonase activity was assessed in serum samples by
measuring the initial rate of paraoxon hydrolysis to yield
p-nitrophenol at 25°C. Serum samples was mixed with an
assay buffer contained 1.2 mmol/l paraoxon, 1.32 mmol/
l CaCl2, 132 mmol/l Tris-base, and 2.63 mmol/l NaCl (pH
8.5). Absorbances were measured at 405 nm wavelength for
3 min in a spectrophotometer. One unit of paraoxonase
activity is defined as 1 μmol of p-nitrophenol formed per
minute, and activity was expressed as units per liter of
serum [26].
Measurement of malondialdehyde level
Serum malondialdehyde levels were measured by the for-
mation of thiobarbituric acid reactive substances (TBARS),
based on spectrophotometric measurement. Serum samples
were mixed with phosphoric acid, butylated hydroxyto-
luene, and thiobarbituric acid. The mixture in tubes was
incubated in boiling water for 30 min and reaction was
stopped with addition the tubes on ice-cold water. MDA
was extracted by the addition of n-butanol and vortexing for
5 min. The measurements of the pink color of the samples
were made with a spectrophotometer at a wavelength of
532 nm. The concentration of TBARS was calculated using
1,1,3,3-tetraethoxypropane as the standard. Results are giv-
en as nanomoles of MDA per milliliter of serum [27].
Statistical analysis
Statistical analyses were performed using SPSS 16.00. Data
are expressed as mean ± SD. Analysis of variance was used
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to find difference between groups and within groups. Non-
parametric variables were compared by the chi-square test
or Fisher’s exact test when the expected value was less than 5.
Statistical significance was accepted as p<0.05.
Results
The patient population consisted of simple snorers, OSAS,
and nocturnal sustained hypoxemic COPD patients. These
patients were not age-matched and there were significant
age differences between groups (43.8±12.9 years, 49.3±
8.5 years, and 57.1±10.4 years, consecutively, p00.005).
The groups were matched for gender, body mass index
(BMI), and smoking histories. History of hypertension was
significantly higher in the COPD and OSA groups than the
control subjects (p00.002). There were no statistical differ-
ences in the history of ischemic heart disease between the
three groups. In the COPD group, there were four smokers,
three non-smokers, and four ex-smokers while there were 10
smokers, 13 non-smokers, and 21 ex-smokers in the OSA
group. In the control group, there were four smokers, four
non-smokers, and six ex-smokers.
Descriptive measurements of clinical properties, noctur-
nal sleep, and respiratory parameters are presented in Table 1.
Serum LDL levels were determined as 127.8±37.1 mg/dl,
111.9±3 2.7 mg/dl, and 117.7±32.2 mg/dl in the OSA,
COPD, and control groups, respectively. There were no sta-
tistically significant differences between groups. HDL levels
were 41.0±7.6 mg/dl, 44.4±13.3 mg/dl, and 42.5±14.0 mg/dl
in OSA, COPD, and control groups, respectively. The HDL
levels also did not show significant differences between
groups.
OSAS and COPD patients showed wide variability in the
severity of nocturnal hypoxemia, with minimum SaO2
ranges 53–92 % and 50–87 %, respectively. Daytime SaO2
of COPD patients was 92.27 % (range 90–95 %) and day-
time arterial carbon dioxide and oxygen pressures were
49.72 and 66.02 mmHg, respectively. The percentage of
total sleep time with an SaO2 <90 % showed a wide distri-
bution range of 33–100 % (mean, 79.7±24.9 %) in COPD
patients.
Table 1 presents TBARS and PON1 levels in the OSA,
COPD, and the control groups. The mean levels of TBARS
were 15.7±3.6 nmol MDA/ml and 15.3±3.4 nmol MDA/ml
in OSA and COPD patients, respectively. The mean TBARS
level in the control group was 4.1±1.2 nmol MDA/ml. Then
mean PON1 levels were 124.2±35.5 U/l in OSA patients
and 124.6±28.4 U/l in COPD patients. The mean PON level
in the control group was 269.0±135.8 U/l. TBARS levels in
COPD and OSA patients were higher than TBARS levels in
controls, while PON1 levels in OSA and COPD patients
were lower than those in the control group (p<0.001 for
TBARS as well as PON1).
Discussion
In the present study, it was found that TBARS levels are
increased and PON1 activity is decreased in both OSA
patients (with cyclic intermittent hypoxia) and COPD
patients (with sustained nocturnal intermittent hypoxia), as
Table 1 Characteristics of the
OSA, COPD and control
subjects
*Values given as mean (range)
unless otherwise noted. BMI
body mass index; AHI apnea-
hypopnea index; ODI oxygen
desaturation index; NA not apli-
cable; LDL low-density lipopro-
tein; HDL high-density
lipoprotein; PON1 paraoxonase-
1; TBARS thiobarbituric reactive
substances; NS not significant.
Variables Control OSAS COPD P value
Demographic and clinical data
Gender
Male/Female 11/3 40/4 8/3 NS
Age, years 49±8.6 44±13.0 57±10.3 P00.005
BMI, kg/m2 31.8±4.9 30.5±4.6 28.2±4.5 NS
Respiratory data
AHI, events/h 2.7±1.0 37.1±23.0 1.7±1.4 P<0.001
ODI, events/h 47.2±25.0 14.7±20.2 P<0.001
Minimum O2 % 90.4±0.9 76.6±10.2 70.2±12.8 P<0.001
%<90% O2 Sat 0 33.0±18.24 79.7±24.9 NA
Biochemical Data
Total cholesterol mg/dL 200.2±42.4 205.7±43.6 197.0±29.3 NS
LDL, mg/dL 117.7±32.2 127.8±37.1 111.9±32.7 NS
HDL, mg/dL 42.5±14.0 41.0±7.6 44.4±13.3 NS
Triglyceride, mg/dL 209.2±144.6 200.5±95.9 151.6±42.1 NS
PON1(U/L) 269.0±135.8 124.2±35.5 124.6±28.4 P00.002
TBARS, nmol MDA/mL 4.1±1.2 15.7±3.6 15.3±3.4 P00.000
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compared to simple snorers. These results showed that noc-
turnal intermittent hypoxemia either cyclic or sustained had
an effect on increased lipid peroxidation and diminished
PON1 activity.
Lipid peroxidation is a major product of an oxidative
stress and is often measured by TBARS method and de-
scribed as MDA equivalents [28]. In our experiment, we
show that TBARS levels in OSA and COPD are higher than
our control subjects. There are several studies about lipid
peroxidation in OSA and COPD patients. Alzoghaibi et al.
found that there was an increased lipid peroxidation
inhibited by continuous positive airway pressure (CPAP)
therapy [29]. Darkova et al. also reported decreased MDA
level with the usage of at least four night CPAP machine
[30]. Vatansever et al. used a high-performance liquid chro-
matography method for measurement of lipid peroxidation
and found that MDA levels were higher in moderate–severe
OSA patients [31]. On the other hand, the level of MDA
were reported to be increased in patients with acute exacer-
bation of COPD compared with healthy smokers in some
studies [32], but Stanojkovich et al. notified that there was
an increase in MDA levels during discharge not in acute
exacerbation of COPD [33]. Our COPD patients were very
stable and they do not require any bronchodilator treatment,
but they all have nocturnal sustained hypoxia throughout the
night. In this perspective, our COPD patients were consid-
ered as stable patients.
LDL oxidation is thought to be a major component in the
pathogenesis of atherosclerosis [34, 35]. Two mechanisms
by which atherogenic-oxidized lipoproteins are removed
from the circulation have been suggested. One mechanism
is an increased cellular uptake of oxidized lipoproteins and
the second is the conversion of oxidized lipoproteins to a
less atherogenic lipoprotein [36, 37]. PON probably has a
role in both these processes. Under oxidative stress, LDL
and HDL are prone to lipid peroxidation. PON is associated
with HDL and protects of HDL, rather than LDL, from the
harmful effects of oxidative stress [38]. Lavie et al. found
significantly lower levels of PON1 activity in OSA patients
with cardiovascular disease than in controls. Lavie’s results
showed that the best correlated parameters were percentage
of time below SaO2 of 9n minimum oxygen saturation, and
the respiratory disturbance index (RDI). Of these, Lavie
found that the RDI was the best predictor of PON1 level.
The authors suggested that abnormal respiratory events
cause multiple hypoxia–reoxygenation cycles (cyclic inter-
mittent hypoxia) and lead to decreases in PON1 levels as
well as the other parameters of lipid peroxidation. In another
study, Vatansever et al. did not find any differences in PON1
activities in OSA patients with respect to their controls, and
they concluded that PON activity differ only in OSA
patients with cardiovascular disease [31]. Stanajkovic et al.
reported similar PON1 activity results in COPD patients that
there was only decreased PON1 activity obtained in ische-
mic heart disease positive COPD patients. The PON1 activ-
ity in our OSA and COPD groups were found to be
significantly decreased according to controls. The only car-
diovascular risk factor in both groups was hypertension, and
it might be a confounding factor to decrease PON 1 levels in
our study [33].
Increased sympathetic responses to hypoxic chemoreflex
stimulation occur in OSA patients. It was reported that
similar responses were obtained from healthy subjects ex-
posed to intermittent hypoxia [39, 40]. A research protocol
showed that extended exposure to intermittent hypoxia with
20–30 cycles/h for 8–9 h/day for up to 4 weeks [41] resulted
in an increased morning blood pressure. These studies sug-
gest that an increase in sympathetic activation emerges in
response to cyclic and sustained drops in oxygen saturation.
Our findings agree with the previous study in which we
showed the similarities of effects of cyclic and sustained
nocturnal oxygen drops on the oxidative stress pathway.
Previously, it was reported that oxidative stress is asso-
ciated with many factors such as hypertension [42, 43],
obesity [44, 45], smoking [46, 47], hyperlipidemia [48],
and diabetes [49, 50]. In our study population, serum total
cholesterol content, HDL and LDL levels, smoking history,
and BMI did not differ significantly between OSA, COPD,
and control groups. Only the history of hypertension was
higher in COPD and OSA groups than in the controls.
Matching cardiovascular confounding risk factors to sex,
age, and BMI is the desired design for this study. However,
our inclusion criteria for the COPD group were very limited.
Matching the three groups was thus not possible for us.
One of the major criticisms of our study is that we
focused solely on PON1 and TBARS levels as oxidative
stress markers. The levels of F2-isoprostane, superoxide
dismutase (SOD), catalase, and erythrocyte glutathione per-
oxidase are commonly studied parameters in both OSA and
COPD patients to show the role of oxidative stress in the
development of cardiovascular disease. PON1 activity was
also an extensively studied parameter in OSA patients [13,
14], but there were very limited data about PON1 in COPD
patients [5, 51]. In the future, it will be helpful to correlate all
of the parameters of oxidative stress in both OSA and COPD
patients to better study the effects of nocturnal hypoxemia.
In conclusion, our results demonstrate decreased PON1
activity and increased TBARS levels in both OSA and
COPD patients in comparison to controls. These results
suggest that reduction in the capacities of antioxidative
enzymes and increases in toxic lipid peroxidation products
might be related to nocturnal hypoxemia. Further studies are
needed to explain the effect of nocturnal cyclic and sus-
tained intermittent hypoxia on the oxidative stress pathway.
All authors declare that they have no conflict of interest
with this report.
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